A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context
File version
Version of Record (VoR)
Author(s)
Johnston, J
Mortimore, R
Robertson, I
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
The use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of a number of hematological conditions is rapidly increasing. Ibrutinib is the most clinically advanced and common BTK inhibitor currently utilized. Its use, however, comes with increasing reports of immunosuppression and increased risk of opportunistic infections.1 We present the case of a widespread papulonodular eruption secondary to disseminated cryptococcal disease after ibrutinib therapy, which the authors believe is the first reported case with widespread cutaneous involvement.
Journal Title
JAAD Case Reports
Conference Title
Book Title
Edition
Volume
13
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2021 Published by Elsevier on behalf of the American Academyof Dermatology, Inc. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
BTK, Bruton tyrosine kinase
dermatology
drug reaction
eruption
hematology
Persistent link to this record
Citation
Van Rooij, N; Johnston, J; Mortimore, R; Robertson, I, A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context, JAAD Case Reports, 2021, 13, pp. 43-45